Mirtazapine Bluefish (Mirtazapine)

Mirtazapine works by blocking central alpha‑2 adrenergic receptors, which increases the release of norepinephrine, and by selectively antagonizing 5‑HT2 and 5‑HT3 serotonin receptors. This dual action raises the levels of norepinephrine and serotonin in the brain, contributing to its antidepressant effect.

The appropriate dose of Mirtazapine Bluefish is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Dosage adjustments are made according to clinical judgment and patient needs.

The safety of mirtazapine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh the potential benefits against possible risks and consider alternative treatments when appropriate. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss options with their doctor.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details, and any necessary import documentation.

Mirtazapine belongs to the NaSSA class, which differs from SSRIs and SNRIs by its combined noradrenergic and specific serotonergic activity. It is often chosen for its sedative properties, appetite‑stimulating effect, and lower incidence of sexual dysfunction, making it useful in patients who experience insomnia or weight loss with other antidepressants.

Mirtazapine Bluefish should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Mirtazapine Bluefish is taken orally, usually once daily in the evening due to its sedative effect. The tablet should be swallowed whole with water and not crushed or chewed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, suicidal thoughts or behavior especially early in treatment, hepatic dysfunction, and cardiac arrhythmias. Patients should be monitored closely for any signs of these conditions and seek immediate medical attention if they occur.

Mirtazapine is contraindicated in patients who are currently taking monoamine oxidase inhibitors (MAOIs) or have a known hypersensitivity to mirtazapine. Caution is advised for individuals with severe hepatic impairment, uncontrolled bipolar disorder, or a history of agranulocytosis.